The in vitro effect of new combinations of carbapenem-β-lactamase inhibitors for Mycobacterium abscessus

  • Antimicrob Agents Chemother. 2023 Sep 6;e0052823. doi: 10.1128/aac.00528-23.
Gabrielle Fröberg  1  2 ,  Ayan Ahmed  1 ,  Erja Chryssanthou  1 ,  Lina Davies Forsman  2  3
Affiliations
  • 1. Department of Clinical Microbiology, Karolinska University Hospital , Stockholm, Sweden.
  • 2. Department of Medicine, Division of Infectious Diseases, Karolinska Institutet , Solna, Sweden.
  • 3. Department of Infectious Diseases, Karolinska University Hospital , Stockholm, Sweden.
PMID: 37671880 DOI: 10.1128/aac.00528-23
Abstract

As new treatment alternatives for Mycobacterium abscessus complex (MABC) are urgently needed, we determined the minimum inhibitory concentrations (MICs) for novel carbapenem combinations, including imipenem-relebactam and tebipenem-avibactam against 98 MABC isolates by broth microdilution. The MIC50 was reduced from 16 to 8 mg/L by adding relebactam to imipenem, while the addition of avibactam to tebipenem showed a more pronounced reduction from 256 to 16 mg/L, representing a promising non-toxic, oral treatment option for further exploration.

Keywords
difficult to treat NTMs; imipenem-relebactam; minimum inhibitory concentrations; new treatment alternatives; tebipenem-avibactam; β-lactam antibiotics; β-lactamase inhibitors.
Products